This is concluded from the observation of frequent somatic, tumour-specific NF2 mutations, and the loss of the second NF2 allele in schwannomas from patients with germline SMARCB1 mutations (Boyd et al. 2008; Sestini et al. 2008; Hadfield et al. 2008, 2010a). This evidence concerns the gene NF2 and schwannoma.